文献速递妇科肿瘤乳腺癌

ERCC3是否为新的卵巢癌易感基因?

ERCC3, a new ovarian cancer susceptibility gene?
PubMed 文献 · Eur J Cancer · 2020-10-23

该研究在1311例疑似遗传性乳腺癌-卵巢癌综合征(HBOC)患者中筛查ERCC3截短变异,发现13例携带者(0.99%),其中5例同时携带其他HBOC高/中 penetrance 基因突变。

要点

  • ERCC3截短变异在疑似HBOC患者中频率为0.99%,对照组为0.22%–0.24%。
  • ERCC3截短变异与卵巢癌风险显著相关(OR=4.74,P=0.028)。
  • 与乳腺癌关联接近但未达统计学显著(OR=2.25,P=0.11)。

核心结论

  • ERCC3截短变异与卵巢癌风险显著相关,为首次发现ERCC3可能增加卵巢癌风险。

研究设计与样本

  • 对1311例无亲缘关系的疑似HBOC患者进行多基因panel筛查ERCC3。
  • 对照为453例西班牙无癌个体及51343例GnomAD非芬兰非癌欧洲个体。

主要发现

  • 13例患者携带杂合ERCC3截短变异(0.99%),其中5例同时携带BRCA1、BRCA2、CHEK2或TP53突变(MINAS)。
  • 西班牙对照中ERCC3截短变异频率为0.22%,GnomAD非芬兰欧洲人群为0.24%。

临床怎么用

  • 对疑似HBOC患者进行多基因panel检测时可关注ERCC3截短变异。
  • 检出ERCC3截短变异者需注意可能合并其他HBOC基因突变(MINAS)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hereditary breast and ovarian cancer syndrome (HBOC) is an inherited disorder with an increased risk of breast cancer (BC) and ovarian cancers (OC). Mutations in BRCA1-BRCA2 explains less than a half of cases. In the last decade several genes with different penetrance have been associated with an increased risk of BC or OC. A recurrent heterozygous ERCC3 truncating mutation increases the risk for breast cancer in patients with Ashkenazi Jewish ancestry. Our study aimed to investigate the role of ERCC3 truncating variants in a cohort of patients with suspicion of HBOC. PATIENTS AND METHODS: ERCC3 screening by multigene-panel analysis in 1311 unrelated patients after our regional consensus for genetic testing in hereditary cancer was done. In addition, 453 Spanish cancer-free individuals and 51,343 GnomAD non-Finnish, non-cancer European individuals were used as control populations. RESULTS: We identified 13 patients with heterozygous ERCC3 truncating variants (0.99%). Five of them also carried a mutation in a high- /moderate-penetrance HBOC gene (BRCA1, BRCA2, CHEK2, and TP53) being Multilocus Inherited Neoplasia Alleles syndrome (MINAS) patients. The frequency in 453 Spanish controls was of 0.22%; similar to that observed in 51,343 non-Finnish European GnomAD population (0.24%). We found an almost statistically significant association of truncating ERCC3 variants with BC (odds ratio [OR] = 2.25, confidence interval [CI] = 0.6-5.93, P = 0.11), and we observed for the first time a significant association with OC (OR = 4.74, CI = 1-14.34, P = 0.028), that holds even after removing MINAS cases. CONCLUSIONS: To our knowledge, this is the largest HBOC series comprehensively analysed for ERCC3 mutations, and the first study identifying ERCC3 as a cancer risk for OC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stradella A, Del Valle J, Rofes P, et al. ERCC3, a new ovarian cancer susceptibility gene? Eur J Cancer. 2020. PMID: 33125943. doi:10.1016/j.ejca.2020.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。